Search Results
Your search for ,foR matches 32687 pages
Showing 29851 - 29900Long-Term Infusion of Immunotherapy May Reduce Pain in Children With High-Risk Neuroblastoma
Changing the infusion delivery method of the monoclonal antibody ch14.18/CHO (dinutuximab-beta, the European counterpart of dinutuximab [Unituxin]) in combination with interleukin-2 and oral 13-cis-retinoic acid from short-term infusion to long-term infusion in the treatment of children with...
Immune System–Boosting Agent May Reduce Early-Stage Melanoma Recurrences
Among patients with clinically stage I or stage II melanoma, those treated with the immune system–boosting agent CpG-B were less likely to experience recurrence of their disease than those who received placebo, according to results from two randomized, placebo-controlled phase II clinical...
Brazilian Wasp Venom May Be Active Against Cancer Cells
The social wasp Polybia paulista protects itself against predators by producing venom known to contain a powerful cancer-fighting ingredient. A Biophysical Journal study published by Bueno Leite et al revealed how the venom's toxin—called MP1 (Polybia-MP1)—may selectively kill cancer...
Genetic Sequencing May Impact Treatment for Children With Rare, Aggressive Cancers
For children with rare, aggressive, and advanced cancer, precision medicine may help doctors determine their best treatment options, a new study found. Using information from a patient's entire genome helped to suggest personalized treatment options for nearly half of children with cancer and...
Higher Failure-to-Rescue Rates in Lung Cancer Resections Reported at Hospitals With High Mortality Rates in Major Cancer Resections
In a retrospective cohort study reported in JAMA Surgery, Grenda et al found higher mortality and higher failure to rescue rates in patients undergoing lung resection at hospitals with high vs low mortality rates in major cancer resections. Study Details In the study, hospitals with the lowest...
Study Explores Link Between Allele Expression and Risk of Graft-vs-Host Disease in Transplant Recipients
In a study reported in The New England Journal of Medicine, Petersdorf et al found a greater risk of acute graft-vs-host disease among hematopoietic cell transplant recipients with the high-expression rs9277534G allele linked to mismatched HLA-DPB1 who received transplants from donors with the...
AACR’s Cancer Progress Report Details Major Advances in Cancer and Rising Costs of Treatment
The American Association for Cancer Research (AACR) 2015 Cancer Progress Report highlighted the accelerated pace of the number of U.S. Food and Drug Administration (FDA)-approved targeted therapies over the past 5 years, which reached 52 this year; the dramatic increase in the 5-year survival rate...
Study Finds No Recurrence-Free Survival Benefit of Adjuvant Sorafenib in Hepatocellular Carcinoma After Resection or Ablation
In the phase III STORM trial reported in The Lancet Oncology, Bruix et al found no benefit with adjuvant sorafenib (Nexavar) treatment in patients who had undergone resection or ablation for hepatocellular carcinoma. Study Details In this double-blind trial, 1,114 patients from 202 sites in 28...
Japanese Phase II Trial Shows Activity of Nivolumab in Platinum-Resistant Ovarian Cancer
In a Japanese phase II trial reported in the Journal of Clinical Oncology, Hamanishi et al found that the anti–PD-1 (programmed cell death protein 1) antibody nivolumab (Opdivo) was active in patients with relapsed or advanced platinum-resistant ovarian cancer. Study Details In the study,...
Persistent Leukemia-Associated Mutations After Induction Therapy Predict Poorer Outcome in AML
In a study reported in JAMA, Klco et al found that persistence of leukemia-associated mutations in ≥ 5% of bone marrow cells at remission predicted poorer outcome among patients with acute myeloid leukemia (AML), including those with intermediate-risk disease. Study Details In the study,...
Statistical Model May Identify Patients Most Likely to Benefit From Mesothelioma Surgery
A new statistical model may help predict which patients are most likely to receive life-extending benefits from surgical treatment for malignant pleural mesothelioma, according to a report published by Leuzzi et al in The Annals of Thoracic Surgery. Malignant pleural mesothelioma is an aggressive...
MicroRNA Panel Shows Early Potential as Biomarker of Pancreatic Precancers
Assessing blood plasma levels of certain microRNAs (miRNAs) distinguished individuals with noninvasive pancreatic precancers from healthy individuals and discriminated between patients with high-risk and low-risk neoplasms, according to a preliminary, proof-of-principle study published by...
Trebananib Plus Sunitinib Active in Metastatic Clear Cell Renal Cell Cancer
In a phase II study reported in the Journal of Clinical Oncology, Atkins et al found that combined treatment with the recombinant peptide-Fc fusion protein trebananib and the vascular endothelial growth factor (VEGF) inhibitor sunitinib (Sutent) was active in metastatic renal cell cancer and...
BRAF Inhibition Successful in Relapsed/Refractory BRAF V600E–Mutant Hairy Cell Leukemia
In two phase II studies reported in The New England Journal of Medicine, Tiacci et al found that the BRAF inhibitor vemurafenib (Zelboraf) produced responses in nearly all patients with BRAF V600E–positive hairy cell leukemia who relapsed after treatment with a purine analog or who had...
ASCO Clinical Practice Guideline Update: Systemic Therapy for Stage IV NSCLC
As reported in the Journal of Clinical Oncology by Masters et al, ASCO has issued a clinical practice guideline update on systemic therapy for stage IV non–small cell lung cancer (NSCLC). Recommendations are based on an update committee systematic review of randomized controlled trials...
Synchronous vs Sequential Tumor Resection in Patients With Advanced Colorectal Cancer
About 20% of patients with colorectal cancer have cancers that have metastasized beyond the colon at the time of their diagnosis, with the liver being the most common site for these metastases. The approach to treating primary tumors within the colon and metastatic tumors in the liver continues to...
Study Explores Link Between Breast Cancer Recurrence Score and Chemotherapy Use
A genetic test that helps predict whether some women’s breast cancer will recur might influence how chemotherapy is used, according to a study from Duke Medicine. The study found that low-risk patients who had the test appeared to opt for more treatment, and high-risk patients who were...
FDA Grants Priority Review to Ixazomib for Patients With Relapsed/Refractory Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has granted Priority Review status to the New Drug Application for the investigational oral proteasome inhibitor ixazomib for the treatment of patients with relapsed or refractory multiple myeloma, Takeda Pharmaceuticals announced. The New Drug...
Internationally Acclaimed Cancer Researcher, Gianni Bonadonna, MD, Dies at 81
Gianni Bonadonna, MD, was considered the “Father of Italian Oncology,” but his scientific contributions to the field and his generous collegial spirit extended far beyond the shores of his native land. Dr. Bonadonna was at the forefront in the battle to convince the surgical...
WCLC: Cetuximab May Improve Survival in Some Patients With EGFR-Positive Squamous NSCLC
Analysis of a large phase III trial (S0819) suggested that adding the epidermal growth factor receptor (EGFR)-targeting monoclonal antibody cetuximab (Erbitux) to chemotherapy benefits survival in patients with squamous cell non–small cell lung cancer (NSCLC) with tumors positive...
WCLC: New Study Reveals Genomic Architecture of EGFR Mutations in Lung Cancer
Epidermal growth factor receptor (EGFR) mutations are one of the most common driver oncogenes in lung cancer, typified by high response rates when treated with tyrosine kinase inhibitors and median progression-free survival of 10 months, commonly due to emergence of T790M. The genomic...
WCLC: Effect of EGFR Protein and EGFR Gene Copy Number in SQUIRE Trial
Previously, researchers reporting on the SQUIRE study demonstrated that the addition of necitumumab to gemcitabine-cisplatin improved overall survival in patients with stage IV squamous non–small cell lung cancer (NSCLC). Following up on these findings, Fred R. Hirsch, MD, PhD,...
WCLC: Adding Bevacizumab to Chemotherapy Does Not Improve Overall Survival in Early-Stage NSCLC
Adding the monoclonal antibody bevacizumab (Avastin) to chemotherapy for patients with surgically removed non–small cell lung cancer (NSCLC) did not improve overall survival, according to research (Abstract PLEN04.03) presented at the 16th World Conference on Lung Cancer (WCLC) in Denver,...
Study Finds Nearly Half of Testicular Cancer Risk Is Inherited
A large European study that combined both population-based and genomic techniques to investigate the heritability of testicular germ cell tumor has found that 48.9% of all the possible factors contributing to risk for the disease are inherited. Rather than being the result of one faulty gene,...
New Agent Targeting Epigenetic Modifications Shows Activity in Advanced Cancer
In a dose-escalation phase I study reported in The Lancet Oncology, Reid et al found that RRx-001, a representative of a new class of compounds called dinitroazetidines (sourced from the aerospace industry) that act on the tumor microenvironment, had activity in advanced cancers and a promising...
FDA Grants Alectinib Priority Review for ALK‑Positive Lung Cancer
Genentech announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) and granted Priority Review for alectinib, an oral investigational anaplastic lymphoma kinase (ALK) inhibitor, for the treatment of people with ALK-positive,...
Final Results of NO16968 Trial Show Improved Overall Survival With Adjuvant XELOX vs Bolus 5-FU/Leucovorin in Stage III Colon Cancer
As reported by Schmoll et al in the Journal of Clinical Oncology, the final results of the phase III NO16968 trial showed that adjuvant therapy with XELOX (capecitabine, oxaliplatin) improved overall survival vs fluorouracil (5-FU)/leucovorin in patients with resected stage III colon cancer....
WCLC: Results From ROMANA Trials of Anamorelin in Advanced NSCLC Patients With Cachexia
Two phase III studies of anamorelin found that the medication effectively combats wasting and increases body weight and lean body mass in certain patients with lung cancer. Results (Abstract ORAL29.01) from the ROMANA 1 and ROMANA 2 phase III trials of anamorelin were presented at the 16th...
WCLC: IASLC Issues Statement on Tobacco Control and Smoking Cessation
The International Association for the Study of Lung Cancer (IASLC) issued a new statement on Tobacco Control and Smoking Cessation on September 7 at the 16th World Conference on Lung Cancer (WCLC) in Denver, Colorado. The statement calls for higher taxes on tobacco products; comprehensive...
WCLC: Bevacizumab Plus Standard Chemotherapy Improves Survival in Mesothelioma
The standard of care for malignant pleural mesothelioma may be poised for change, judging by results from a study (Abstract ORAL11.01) by the French Cooperative Thoracic Intergroup. The addition of bevacizumab (Avastin) in the first-line setting to the current standard of care, pemetrexed...
WCLC: Impact of Time to Drug Approval on Potential Years of Life Lost
Every hour lost to the cancer drug regulatory process costs 29 life-years lost in the United States and 260 life-years worldwide, according to research (Abstract ORAL12.05) presented on September 7 at the 16th World Conference on Lung Cancer hosted by the International Association of the...
Improved Overall Survival With FOLFOXIRI/Bevacizumab vs FOLFIRI/Bevacizumab in First-Line Treatment of Metastatic Colorectal Cancer
In an updated analysis of the Italian phase III TRIBE trial reported in The Lancet Oncology, Cremolini et al found that FOLFOXIRI (fluorouracil [5-FU], leucovorin, oxaliplatin, irinotecan) plus bevacizumab (Avastin) significantly prolonged overall survival in patients with unresectable metastatic...
Dose Equivalence Analysis Indicates Reduced Risk of Late Heart Failure With Daunorubicin vs Doxorubicin in Survivors of Childhood Cancer
In a study reported in the Journal of Clinical Oncology, Feijen et al found that daunorubicin may be associated with reduced risk of late heart failure vs doxorubicin in survivors of childhood cancer. Study Details The study included data from 15,815 survivors of childhood cancer who survived...
BRAF V600 Mutation Appears to Be Targetable Oncogene in Some but Not All Nonmelanoma Cancers
In a phase II histology-independent basket study reported in The New England Journal of Medicine, Hyman et al found that the BRAF V600 kinase inhibitor vemurafenib (Zelboraf) exhibited activity in some but not all nonmelanoma cancers with BRAF V600 mutations. Study Details In the study, 122...
Online Database Helps Organize Clinically Important Cancer Gene Mutations
Many clinical trials use genome sequencing to learn which genetic mutations are present in a patient’s tumor cells. The question is important, because targeting the right mutations with the right drugs can stop cancer in its tracks. But it can be difficult to determine which particular...
Phase II Trial Shows Greater Activity With Lenalidomide/Rituximab vs Lenalidomide in Recurrent Follicular Lymphoma
In a phase II trial (Cancer and Leukemia Group B 50401/Alliance) reported in the Journal of Clinical Oncology, Leonard et al found that the addition of rituximab (Rituxan) to lenalidomide (Revlimid) produced a higher response rate and longer time to progression than lenalidomide alone in patients...
Sham and Real Electroacupuncture Reduce Hot Flashes vs Gabapentin and Pill Placebo in Breast Cancer Survivors
In a study assessing placebo effects reported in the Journal of Clinical Oncology, Mao et al found that sham electroacupuncture produced a greater reduction in hot flashes than placebo pills and gabapentin, with the greatest reduction being achieved with real electroacupuncture. Study Details In...
Stiffer Breast Tissue in Obese Women May Promote Tumor Growth
Women who are obese have a higher risk and a worse prognosis for breast cancer, but the reasons why remain unclear. A Cornell study published by Seo et al in Science Translational Medicine suggests that obesity changes the consistency of breast tissue in ways that predispose an individual to tumor...
Survivors of Childhood Cancer Have High Risk of Recurrent Stroke
Recent evidence suggests that survivors of childhood cancer have a high risk of suffering a stroke at a surprisingly young age. A new study from the UC San Francisco Pediatric Brain Center shows that childhood cancer survivors suffering one stroke have double the risk of suffering a second stroke...
Increased Risk of Cancers After Age 40 in Childhood Cancer Survivors
In an analysis from the Childhood Cancer Survivor Study reported in the Journal of Clinical Oncology, Turcotte et al found that survivors of childhood cancer are at increased risk of subsequent malignant neoplasms after age 40 years. Study Details The study involved data from 3,171 survivors of...
Increased Risk of Intestinal Obstruction and Mortality in Survivors of Childhood Cancer
As reported by Madenci et al in the Journal of Clinical Oncology, an analysis from the Childhood Cancer Survivor Study showed that childhood cancer survivors are at increased risk of intestinal obstruction requiring surgery at ≥ 5 years after cancer diagnosis and poorer overall survival. Study...
FDA Approves Rolapitant for Prevention of Chemotherapy-Induced Nausea and Vomiting
The U.S. Food and Drug Administration (FDA) approved rolapitant (Varubi) to prevent delayed-phase chemotherapy-induced nausea and vomiting. Rolapitant is approved in adults in combination with other antiemetic agents that prevent nausea and vomiting associated with initial and repeat courses of...
Call for APOS 2016 Award Nominations
The American Psychosocial Oncology Society (APOS) will be celebrating 30 years of psychosocial oncology at the 13th Annual APOS Conference, to be held March 3 to 5, 2016, in San Diego. Colleagues, mentors, students, and others who have made an impact on psychosocial oncology can be nominated for an ...
New 'Mutation-Tracking' Blood Test Could Predict Breast Cancer Relapse
Scientists have developed a blood test for breast cancer that may be able to identify which patients will suffer a relapse after treatment, months before tumors are visible on hospital scans. The test may uncover small numbers of residual cancer cells that have resisted therapy by detecting cancer...
Combination of Chemotherapy and T-Cell Immunotherapy May Provide Novel Treatment Strategy for Glioblastoma
A preclinical study has found that a combination of decitabine and T-cell immunotherapy demonstrated antitumor activity against glioblastomas in mouse models and was about 50% effective at curing the disease. The results, reported by Everson et al in Neuro-Oncology, show an innovative,...
Pooled Analysis Shows Improved Outcomes With Continuous vs Fixed-Duration Therapy in Newly Diagnosed Multiple Myeloma
In a pooled analysis of trials assessing novel agent-based continuous therapy vs fixed duration of therapy reported in the Journal of Clinical Oncology, Palumbo et al found that continuous therapy prolonged progression-free survival, progression-free survival-2 (time to second progression or...
FDA Accepts for Priority Review the Biologics License Application for Elotuzumab for the Treatment of Relapsed Multiple Myeloma
Bristol-Myers Squibb and AbbVie today announced that the U.S. Food and Drug Administration has accepted for priority review the Biologics License Application for elotuzumab, an investigational signaling lymphocyte activation molecule (SLAMF7)-directed immunostimulatory antibody, for the...
ASCO Releases Updated Policy Statement on Genetic and Genomic Testing for Cancer Susceptibility
The American Society of Clinical Oncology (ASCO) issued an updated policy statement on genetic and genomic testing for cancer susceptibility. Published in the Journal of Clinical Oncology, the statement reviews the ways in which new technologies are transforming the assessment and identification of ...
AAV2 Virus May Be Linked to Hepatocellular Carcinoma in Patients With No History of Cirrhosis or Other Risk Factors
More than a cause of a simple infection, viruses are often involved in the development of serious diseases. Such is the case with liver cancer, which often develops in an organ that has been weakened by hepatitis B or C virus. Researchers at Inserm, the Paris Public Hospitals (AP-HP), Paris...
High Use of Complementary or Alternative Medicines in Older Patients With Cancer
Alternative medicines are widely thought to be at least harmless, and very often helpful, for a wide range of discomforts and illnesses. However, although they’re marketed as “natural,” they often contain active ingredients that can react chemically and biologically with other...
